Interaction between genetics and the adherence to the Mediterranean diet: the risk for age-related macular degeneration. Coimbra Eye Study Report 8.

"Declarations Ethics approval and consent to participatePatients signed the informed consent after explanation of study procedures and possible consequences. The studies obtained the Association for Innovation and Biomedical Research on Light and Image (AIBILI)’s Ethics Committee approval. Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal (AMD IncidencePT); NCT02748824, Number of the study in the Ethics Committee: CE219; Lifestyle and Food Habits Questionnaire in the Portuguese Population Aged 55 or More; NCT01715870, Number of the study in the Ethics Committee: CE 184. Consent for publicationThe informed consent form signed by participants referred data would be used for publication. Competing interestsPB, RC, MLC declare they have no competing interests. CF is a consultant for Bayer and Novartis; YL is a recipient for Novartis and a consultant for Bayer; CBH is a consultant for Bayer, Novartis, Horus Pharma, Abbvie and Horama. He is also a co-founder of Astherna; JCV is a consultant for Carl Zeiss Meditec, Ciana Therapeutics, Alimera Sciences, Boehringer Ingelheim, Allergan, Bayer, Gene Signal, Novartis, Pfizer, Oxular, Roche, Sanofi, Vifor Pharma and Adverum Biotechnologies; RS is a consultant for Alimera, Abbvie, Novartis, Bayer, Roche, Thea and Novo Nordisk. Competing interests PB, RC, MLC declare they have no competing interests. CF is a consultant for Bayer and Novartis; YL is a recipient for Novartis and a consultant for Bayer; CBH is a consultant for Bayer, Novartis, Horus Pharma, Abbvie and Horama. He is also a co-founder of Astherna; JCV is a consultant for Carl Zeiss Meditec, Ciana Therapeutics, Alimera Sciences, Boehringer Ingelheim, Allergan, Bayer, Gene Signal, Novartis, Pfizer, Oxular, Roche, Sanofi, Vifor Pharma and Adverum Biotechnologies; RS is a consultant for Alimera, Abbvie, Novartis, Bayer, Roche, Thea and Novo Nordisk."

"Funding The AMD Incidence Study (NCT02748824) study was funded by Novartis."

"Trial registration The AMD Incidence (NCT02748824) and Lifestyle and Food Habits Questionnaire in the Portuguese Population Aged 55 or More (NCT01715870) studies are registered at www.clinicaltrials.gov. Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal (AMD IncidencePT); NCT02748824: date of registration: 22/04/16. Lifestyle and Food Habits Questionnaire in the Portuguese Population Aged 55 or More; NCT01715870: date of registration: 29/10/12."